Telix Pharmaceuticals Ltd

The Alpha360 growth score reads the multi-year trajectory of revenue, earnings and cash flow, rewarding durable compounding over one-off jumps. Revenue, earnings and cash flow have been expanding quickly, which is what you want from a business that is scaling. Growth off a small base can be lumpy, so the real question is how durable it proves. That trajectory is anchored by three-year revenue growth of 93.5%.

The Alpha360 capital-market score measures the shares' price strength and momentum against the market. The shares have lagged the market with poor momentum, which can flag either a value opportunity or a business the market has turned against. Over the past year the shares are down 41.0%.

The Alpha360 financial-strength score stress-tests the balance sheet, its leverage, liquidity and capacity to fund itself. The balance sheet is stretched: heavier debt or thin liquidity leaves the company more exposed if trading weakens or funding tightens. It runs a current ratio of 1.43.

The Alpha360 analyst-sentiment score reads the direction of professional ratings, targets and forecasts. Analysts have been turning more positive, nudging ratings, targets and estimates higher, which often lends support to the shares from here.

The Alpha360 earnings score grades the quality, consistency and margin of profit, not just its headline size. Earnings are weak or erratic, with thin or negative margins, so profitability is currently unreliable. Net profit margin runs at -0.9%.

The Alpha360 efficiency score measures how much profit the business earns on each dollar of capital and revenue. The business earns poor returns on the capital invested in it, so it is not using its asset base efficiently right now. Return on equity comes in at -1.1%.

The Alpha360 cash-flow score gauges the strength and durability of the cash the business actually generates. Cash flow is weak or negative, so the company may need to raise capital or draw on reserves to fund itself. Cash flow returns come in at -1.5%.